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ture: Effects of PDGF and TGF-b on synthesis and splicing.
Background. Enhanced synthesis of extracellular matrix pro-
teins including fibronectin (FN) is associated with the develop-
ment of sclerosis. In this context we studied FN synthesis by
tubular epithelial cells in response to transforming growth fac-
tor-b (TGF-b) and platelet-derived growth factor (PDGF).
Methods. FN protein synthesis by human tubular epithelial cells
in culture (TEC) was measured by biosynthetic labeling and
ELISA. Splicing of FN was assessed by RT-PCR and by Northern
blotting.
Results. Cultivated TEC synthesized and released FN, the
majority of which was deposited as an unsoluble protein and a
minor portion (10 to 15%) was released into the supernatant.
TGF-b and, to a lesser degree, PDGF, up-regulated FN synthesis.
All three FN splice variants (EDA, EDB, and IIICS) were
produced. PDGF did not influence the splicing. TGF-b preferen-
tially up-regulated the EDA splice variant, but had no effect on
the splicing of the other domains.
Conclusions. PDGF and TGF-b both up-regulate FN synthesis
of TEC. TGF-b, but not PDGF, also changed the quality of the de
novo synthesized FN, and thus has a different role in the
development of sclerosis.
Accumulation of extracellular matrix proteins has been
described in many inflammatory processes, including glo-
merulonephritis and interstitial nephritis [1–4]. In addition
to hypercellularity, most probably due to the influx of
inflammatory cells and increased proliferation of local cells,
deposits of matrix proteins contribute to the development
of sclerosis and eventually to the loss of kidney function.
Inflammatory cytokines, particularly transforming growth
factor-b (TGF-b) [5, 6], generated during acute inflamma-
tion may initiate an excessive production of extracellular
matrix proteins concomitantly with a reduction of the
proteolytic and collagenolytic enzymes [7–9].
Among the extracellular matrix proteins found in scle-
rotic areas is fibronectin, a non-collagenous protein that
participates in wound healing and is also associated with
the development of fibrosis [10, 11]. In various forms of
chronic renal disease and in experimentally-induced tubu-
lar injury deposits of fibronectin are found in the intersti-
tium, as well as along the tubular basement membrane [9,
12–15]. Interstitial fibroblasts and tubular epithelial cells
are the most likely producers of fibronectin, an assumption
supported by studies with primary tubular epithelial cells in
culture [16, 17].
Fibronectin is a rather versatile protein. Though encoded
by a single gene, due to alternative splicing and post-
translational modifications it may assume different forms
and most probably also different functions [18, 19]. Three
distinct splice sites have been identified, and are termed
EDA, EDB and IIICS in humans, or EIIIA, EIIIB and V in
rats. EDA and EDB are encoded by a single exon within
the type III homology domain. They may be deleted from
the mature protein independently of each other. Also, the
IIICS region may be excluded, either partially or com-
pletely, giving rise to five variants. By combining different
splice variants, at least 20 fibronectin isoforms may be
generated. There is evidence that during development
[18–22], wound healing [23] or after malignant transforma-
tion of cells [24] different splice products are synthesized.
Cytokines such as transforming growth factor-b (TGF-b)
appear to affect splicing [25, 17]. Previously, we described
that TGF-b up-regulated fibronectin synthesis of human
tubular epithelial cells in culture and preferentially induced
synthesis of the splice variant EDA [17]. These data are in
good agreement with reports by others, who described a
close correlation between TGF-b expression and EDA-FN
deposition in experimentally-induced nephritides in rats
[13, 26].
We now examined the effect of TGF-b on the other FN
splice variants as well as the effect of the platelet-derived
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growth factor, PDGF, another cytokine associated with
chronic inflammation and sclerosis in the kidney [27, 28].
We found that: (1) tubular epithelial cells produce all FN
splice variants; (2) TGF-b as well as PDGF up-regulated
the FN synthesis; and (3) TGF-b, but not PDGF, affected
the splicing of the EDA domain.
METHODS
Cultivation of human tubular epithelial cells
Tubular epithelial cells (TEC) were prepared and char-
acterized as previously described [17], essentially following
the protocol of Trifillis, Regec and Trump [29]. In brief,
tissue was obtained from patients undergoing nephrectomy
due to renal carcinoma. Only histologically normal tumor-
free tissue was used for the preparation. The fibrous
capsule was removed and tissue from the outer cortex was
cut into pieces of approximately 1 mm3. The tissue was
treated with 230 U/ml collagenase (Sigma Mu¨nchen, Ger-
many) for 30 minutes at 37°C. TEC were isolated by
sequential sieving procedures as discribed by Trifillis et al
[29]. TEC were washed three times with DMEM (Gibco,
Eggenstein, Germany) and then suspended in DMEM
containing 10% fetal calf serum, 1% antibiotics, 0.1%
insulin (5 mg/ml), 1% BME (all obtained from Gibco) in a
concentration of 4 3 105 cells/ml. The cells were placed in
a 24-well culture dish (NUNC GmbH, Wiesbaden-Biebrich
Germany). After two days, the cells were rinsed with
DMEM. Confluent cells were subcultivated and after re-
moval with trypsin-EDTA 103 (Gibco) diluted 1:10 in
phosphate-buffered salt solution (PBS) pH 7.4. The cells
were passed every four days. All experiments were per-
formed using cells of passages 3 to 4. TEC were identified
by: (1) characteristic polygonal or cobblestone-shaped mor-
phology; (2) expression of the surface antigens aminopep-
tidase M and angiotensinase A; and (3) expression of
cytokeratin detected by indirect immunofluorescence.
RNA extraction and hybridization
TEC (106) were washed in 0.9% NaCl solution and RNA
was extracted by acid guanidium isothiocyanate-phenol-
chloroform according to the method of Chomczynski and
Sacchi [30]. The total amount of RNA was quantitated
based on its absorption at 260 nm. Eight to ten mg of total
RNA was electrophoresed in an 1% agarose gel with 2.2 M
formaldehyde, transferred to nylon membranes (Gene
Screen, Du Pont, Dreieich, Germany) by capillary blotting
in 10 3 SSC (NaCl 1,5 M, sodium citrate 0,15 M, pH 7.0) and
cross linked by UV illumination (UV Stratalinker; Strat-
agene, Heidelberg, Germany) at 254 nm for two minutes.
After blotting, the filters were rinsed and prehybridized in
Church buffer (sodium phosphate 0.25 M, pH 7.2, 5 mM
EDTA and 7% SDS) [31] for two to four hours at 65°C.
cDNA probes for fibronectin [32], the EDA alternatively
spliced exon [17] and GAPDH (ATCC, Rockville, MD,
USA) were labeled using a random priming kit (Boehr-
inger, Mannheim, Germany) strictly following the instruc-
tions given by the manufacturer. The labeled probe was
added to the filters and hybridized overnight. After hybrid-
ization the membranes were washed in 2 3 SSC (0.15 M
sodium chloride and 0.015 M sodium citrate adjusted to pH
7.0) with 1% SDS for 30 minutes at 65°C, followed by 0.2 3
SSC with 1% SDS at 65°C for 10 minutes twice. The filters
were exposed to Kodak X-Omat at 270°C for different
times, dependent on the signal intensity. After stripping
they were rehybridized with GAPDH cDNA as housekeep-
ing gene. Relative mRNA levels were determined by
densitometric scanning (Computer 1D image analyzer;
Pharmacia, Freiburg, Germany). Data were corrected for
the respective GAPDH value. The relative increase in
abundance of FN-mRNA was calculated as N-fold increase
over the respective medium control, that is, TEC cultivated
under similar culture conditions and for the same time but
without addition of cytokines.
Analysis of alternative splicing of fibronectin pre-mRNA
by polymerase chain reaction
Alternative splicing of fibronectin RNA was detected by
reverse transcribed-polymerase chain reaction (RT-PCR)
or radioactive PCR essentially as described in [33] with
minor modifications. To detect EDA, primers correspond-
ing to the EDA alternatively spliced exons (267 bp) were
used as described [17].
Alternative splicing of the EDB region of fibronectin
mRNA was detected by RT-PCR using primers flanking
the EDB region (EDB1: 59CCCCTACAAACGGCCAG-
CAGGG 39 and EDB2 59GCCAGTTGGGGAATCAA-
GACCTG 39). Primers were synthesized according to the
cDNA sequence, which generated two PCR products, one
with 458 bp corresponding to the FN-EDB2 and one at 731
bp corresponding to FN-EDB1. To quantify the ratio
between FN containing the EDB region, and FN without
the EDB region, a radioactive RT-PCR was performed.
Synthesis was carried out in a 20 ml reaction volume
containing 2 mg of total RNA, 3.3 mM of a random primer,
and 40 U M-MuLV reverse transcriptase (Boehringer).
One microliter of the first strand cDNA synthesis mixture
was added to the amplification reaction mix containing 20
mM dNTP, 2 mCi of [a32-P]-dCTP, 1 unit Taq DNA
polymerase and 50 pmol of each primer in a final volume of
50 ml. Amplification was performed in a DNA thermocycler
(Perkin Elmer, U¨berlingen, Germany) as follows: initial
denaturation at 95°C for five minutes, 25 cycles of amplifi-
cation (1 min at 95°C, 1 min at 70°C, 1 min at 73°C), and
final extension at 73°C for five minutes. DNA fragments
were analyzed by electrophoresis on 5% polyacrylamide
gels. The gels were then dried under vacuum and exposed
on Kodak X-Omat film. PCR products were quantitated by
scintillation counting of excised bands. For each sample at
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least three independent RT-PCR reactions were carried
out.
To analyze the IIICS region a PCR with primer pairs
flanking the region was performed (PCS1: 59 TTTAAAGC-
CTGATTCAGACATTCG 39; PCS2: 59 GGGAACCGA-
ATATACAATTTATGTC 39) cDNA synthesis and the
amplification were done as described above except that
only 5 pmol of each primer were used at an annealing
temperature of 40°C. To distinguish between the V95 and
the V89 variant a PCR with one primer flanking the
respective region and one internal primer was performed
(PCS4 59 TAGTCTACATCTTCCCTGGG 39; PCS3 59
TTCCCCAACTGGTAACCCTT 39) [33].
FN protein synthesis was either measured by ELISA or
by biosynthetic labeling. For the ELISA a commercially
available kit (TaKaRa; Dianova, Hamburg, Germany) was
used. Cell free supernatants, cell lysates and urea-solubi-
lized extracellular matrix (the latter diluted 1:10 in PBS)
were stored at 220°C before use and applied in a volume of
20 ml. One concern was that the solubilization of the
deposited fibronectin by urea may cause a denaturation of
fibronectin, thereby changing its reactivity with the antibod-
ies; on the other hand, the remaining urea might also affect
the antibodies in the ELISA, thereby modifying the results.
Control experiments with standard protein diluted in urea,
however, showed no major differences when compared to
tests done with the usual buffer system, suggesting that the
data were reliable.
Biosynthetic labeling
Protein synthesis was quantitated by biosynthetic label-
ing with [35S]-methionine. Cells of passages 3 to 4 were
washed with DMEM without additives and incubated with
0.5 ml medium at 37°C, using UltroserTM (2%) as the FCS
substitute. After adding the respective stimuli, medium
containing 100 mCi/ml [35S]-methionine (1000 Ci/mmol; Du
Pont, Dreieich, Germany) was added. After either 24, 48 or
72 hours, the cell supernatants were removed, the remain-
ing cells were washed and lysed with cold cell-lysis buffer
(PBS, 0.01 M EDTA, 0.001 M PMSF, 0,01% NaN3, 1 mg/ml
CHAPS). Cell supernatants and cell lysates were centri-
fuged at 10000 3g at 4°C for 15 minutes to remove cell
debris. Then, the FN was isolated by adsorption to gelatin-
sepharose 4B (Pharmacia, Uppsala, Sweden) as described
in [44]. In brief, 100 ml of the gelatin-sepharose suspension
were added to each sample. Following incubation at 4°C
with constant mixing overnight, the gelatin-sepharose
beads were recovered by centrifugation. After washing
three times with 0.15 NaCl containing 0.5% Triton X-100
and 25 mM Tris-HCl, pH 7.4, fibronectin was released by
resuspending the beads in SDS-sample buffer and heating
to 100°C for two minutes. Relased FN was identifed by
Western blotting (see below).
Fibronectin extraction from extracellular matrix
After removal of the cell lysates, the matrix attached to
the bottom of the wells was solubilized in 8 M urea, 50 mM
Tris-HCl, pH 7.5. For Western blotting an SDS-sample
buffer was added and the samples were boiled for two
minutes. Protein content was estimated by the Lowry
method.
Western blotting
Samples isolated from the cell supernatant or the cell-
lysate, or the solubilized extracellular matrix were electro-
phoresed on 9% polyacrylamide gels and electroblotted
onto nitrocellulose (0.45 mm; Schleicher & Schuell, Dassel,
Germany) by dry-transfer. The nitrocellulose filter was
incubated with 2% casein in TBS for two hours or over-
night. To detect fibronectin, peroxidase conjugated sheep
anti-human fibronectin and anti-sheep IgG (Binding-Site,
Heidelberg, Germany) were used. After developing the
substrate reaction, the filters were dried and exposed to
Kodak X-Omat at 270°C for two to three days. The stained
regions from the filters were cut out and the radioactivity
was counted. [35S]-methionine incorporation into fibronec-
tin was expressed as counts per minute, and used as an
indicator of de novo fibronectin synthesis.
Fig. 1. Identification of fibronectin by biosynthetic labeling with [35S]-
methionine and SDS-PAGE and Western blotting: TEC were cultivated in
the presence of [35S]-methionine for 24 hours. The cell supernatant (lane
3) and the cell lysates (lane 2) were absorbed to gelatin sepharose and
after elution subjected to SDS-PAGE followed by autoradiography. The
deposited extracellular matrix (lane 1) was solubilized with urea and then
separated by SDS-PAGE. In parallel, a Western blot was performed with
a polyclonal antibody to human FN (left lane).
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Determination of PDGF and TGF-b
PDGF and TGF-b were measured in cell-free superna-
tants with a commercially available ELISA-Kit (Quan-
tikine; R&D Systems Europe, Abingdon, UK) and ex-
pressed in pg per ml supernatant of approximately 1 3 105
TEC.
Statistical analysis
Comparisons between means were made by using a
two-population t-test.
RESULTS
Tubular epithelial cells in culture synthesize large
amounts of fibronectin (FN), which is partly released into
the supernatant and partly is deposited onto the culture
plates. Fibronectin was not found on the cell surface as
measured by cytofluorometry (data not shown). To analyze
the distribution of de novo synthesized FN, TEC were
cultured in the presence of [35S]-methionine. After 24
hours, the supernatant was harvested and the cells were
removed and lyzed. FN was isolated by absorption to
Fig. 2. TGF-b and PDGF in the supernatant of
cultivated TEC. (A) TEC were cultivated for
various times with (grey bar) or without (hollow
bar) PDGF (1 ng/ml). Then PDGF (lower
panel) or TGF-b (upper panel) was measured
in the cell supernatant by ELISA. The values
represent the mean of triplicates and are
expressed as pg FN per ml supernatant. (B)
TEC were cultivated for various times with
TGF-b 2 ng (dark grey bar), TGF-b 0.2 ng
(grey bar) or without TGFb (hollow bar).
Again, PDGF (lower panel) or TGF-b (upper
panel) were measured as described above. Note
that the two experiments were done with
different TEC, which might explain the
differences in the spontaneous cytokine release.
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gelatin-sepharose and subjected to SDS-PAGE. The depos-
ited matrix was solubilized in 8 M urea. By SDS-PAGE
combined with autoradiography and Western blotting,
three major FN forms could be identified with apparent
molecular weights of 200, 240 and 265 kD. The supernatant
contained mainly the 265 kD FN, the lysate a major band at
200 kD, and there was a faint band at 265 kD (Fig. 1). The
radioactivity associated with the FN bands was counted.
From the experiment shown in Figure 1 and other similar
experiments it was calculated that approximately 80% of
the de novo synthesized FN appeared in the matrix; 10 to
15% were found in the cell supernatant, 5 to 10% in the cell
lysate. By ELISA, the data could be confirmed: in one
experiment with 1.5 3 105 TEC per well 50 ng FN was
found in the supernatant, 27 ng in the cell lysate and 300 ng
in the extracellular matrix (data are mean of triplicate
experiments). Independent experiments gave essentially a
similar distribution of FN; however, the absolute amounts
of FN were rather variable.
In another set of experiments the effects of TGF-b and
PDGF on FN synthesis were tested. Both cytokines may
also be produced by TEC. Under our culture conditions,
PDGF was found in the cell supernatant, accumulating to
up 400 pg per ml cell supernatant within 72 hours (a
representative experiment is shown in Fig. 2). The addition
of PDGF or TGF-b did not cause a considerable increase
in PDGF synthesis (Fig. 2). Also, TGF-b was found in the
cell supernatant, again accumulating with time in culture.
Exogenously added PDGF did not increase TGF-b release;
however, TGF-b itself caused an up to twofold increase of
TGF-b, but only after 72 hours (Fig. 2). Consequently,
autocrine or paracrine stimulation is not expected to ob-
scure the effects of exogenously added PDGF or TGF-b.
The rather delayed effect of TGF-b was also seen when
FN synthesis was studied. Only after 24 to 48 hours
exposure to TGF-b was the abundance of FN-specific
mRNA increased (Table 1), whereas PDGF had already
caused about a twofold increase at between two and four
hours (Fig. 3).
The different kinetics of the TGF-b- and PDGF-medi-
ated effects were also seen when studying FN protein
synthesis by biosynthetic labeling. TGF-b and to a lesser
extent PDGF enhanced FN protein synthesis. After culti-
vation with TGF-b for 72 hours about threefold (3.4 6
0.95; mean of 3 independent experiments) more FN was
found in the deposited matrix than in the matrix of
untreated TEC; in the cell supernatant only a slight though
statistically significant increase (6 40%) of FN was found.
The effect of PDGF was less pronounced. At a maximum
about 80% more FN was found in the matrix after 24 hours,
while in the supernatant a minor increase of FN was seen
only in some experiments. The findings could be confirmed
by measuring FN by ELISA (Fig. 4).
Next, the effects of TGF-b and of PDGF on the FN
splicing was tested. Approximately 30% of the de novo
synthesized FN contains EDA as determined by RT-PCR
(Fig. 5). After stimulation with TGF-b, the portion of
EDA-containing mRNA increased to about 45% of total
FN, suggesting that TGF-b preferentially up-regulated
EDA-containing FN. Stimulation of TEC with PDGF,
though resulting in an increase of total FN mRNA, did not
up-regulate the EDA splice variant (Figs. 3 and 5).
Next, the presence of the EDB splice variant was tested.
Since it is known from work by others that EDB is present
only in small amounts, a PCR with radiolabeled dCTP and
primers flanking the EDB region was performed. After
separating the PCR products two bands were found, one
corresponding to 458 bp and and one to 731 bp (Fig. 6). By
cloning and sequencing the 458 bp PCR product was
identified as FN lacking EDB, the 731 bp as the EDB-
containing form. From 10 independent experiments it was
calculated that the latter amounted to approximately 5% of
the total FN.
To see whether stimulation of TEC with either PDGF or
TGF-b affected the synthesis of EDB-FN, TEC were
cultivated with PDGF for two hours or with TGF-b for 24
hours. Under neither condition did the intensity of the
EDB-FN band increase relative to the EDB2-FN band.
Next the IIICS region was analyzed by PCR using
radiolabeled dCTP and primers flanking the respective
domains. The majority of FN contained the splice variants
Fig. 3. Expression of FN mRNA in TEC after stimulation with PDGF.
TEC were incubated for various times with (1) or without (2) PDGF (1
ng/ml). Then total RNA was isolated and Northern blots were performed
with FN specific cDNA probe (upper panel), a cDNA specific for EDA
(middle panel) and for comparison with GAPDH (lower panel).
Table 1. Effect of TGF-b and of PDGF on FN mRNA measured as
relative increase in abundance compared to unstimulated TEC
TEC stimulated with TGF-b 1 ng/ml, 48 hr PDGF 1 ng/ml, 2 hr
FN mRNA 3.6 6 0.9a 2.0 6 0.33a
EDA mRNA 7.1 6 1.1a 1.0 6 0.24
Abbreviations are: TGF-b, transforming growth factor-Beta; PDGF,
platelet-derived growth factor; FN, fibronectin; TEC, tubular epithelial
cells.
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V89/V95, but also the full length IIICS region (V120) and
FN lacking the CS1 and the CS5 regions (V64) were
synthesized (Fig. 7). To distinguish between V95 and V89,
a PCR was done using a 59primer within the CS1 region
(PCS3) and a 39primer flanking the IIICS region (PCS1).
After separation on a 5% polyacrylamide gel, V120 and
V89 could be identified (Fig. 7B). Amplification with
another primer pair, the 59 primer binding outside IIICS
(PCS2), the 39primer binding within the CS5 region (PCS4)
again yielded two bands, one corresponding to V120 the
other to V95 (Fig. 7).
Taken together, the data indicate that TEC synthesize all
IIICS splice variants.
Fig. 4. Fibronectin synthesis by TEC after
stimulation with TGF-b or with PDGF. TEC
were cultivated in the absence (hollow bar) or
presence of either TGF-b (0.2 ng/ml; grey bar)
or PDGF (2 ng/ml; hatched bar) for various
times. Then FN was measured in the cell
supernatant (right panel) or in the solubilized
deposited matrix proteins (left panel) by
ELISA. The data are the mean of five
replicates.
Fig. 5. Determination of the EDA splice variant in TEC. TEC were
cultivated in medium with TGF-b (24 hr) or PDGF (2 hr), and then RNA
was isolated and RT-PCR was performed with primers flanking the EDA
coding region. The PCR products are separated on agarose gels and
visualized by ethidium bromide staining (M size marker, - unstimulated
TEC).
Fig. 6. Determination of the EDB splice variant in TEC. TEC were
cultivated in medium, with TGF-b (24 hr) or PDGF (2 hr); then RNA was
isolated and RT-PCR was performed with [32P]dCTP and primers flanking
the EDB coding region. The PCR products are separated on polyacryl-
amide gels and visualized by autoradiography (- unstimulated TEC).
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To test the effect of TGF-b, the splice pattern was
determined after stimulation for either 12 or 24 hours when
the abundance of FN mRNA was high. No differences of
the band pattern were apparent (Fig. 7D). Also, after
stimulation with PDGF all PCR products were still present;
in independent experiments the V120 and the V95/V89
appeared less intense when TEC were maximally stimu-
lated (after 2 and 4 hr) as opposed to unstimulated cells.
(one example is shown in Fig. 7C)
DISCUSSION
Human tubular epithelial cells in culture synthesize
fibronectin, predominantly as a rather stable, water-insol-
uble deposit on the culture plate. After solubilization by
urea and separation by SDS-PAGE three major protein
bands with different apparent molecular sizes, 200, 240 and
265 kD, were found. The nature of these different fibronec-
tins was not analyzed further. Most probably, the 240 kD
and the 265 kD bands represent fibronectin post-transla-
tionally or even extracellularly modified, because there is
only one form found intracellularly. A minor portion (10 to
15%) of the de novo synthesized fibronectin is released into
the supernatant, also as a protein of larger size.
Tubular epithelial cells produce all the three splice
variants of FN, though FN containing EDB represents only
a minor portion of total FN (6 5%). EDA is found in
approximately 30% of the FN and also all variants of the
IIICS region, including CS1, which encodes for the cell-
attachment region for VLA-4.
In many cells including TEC splicing of FN is affected by
cytokines [17]. In our experiments splicing at the EDB site
appeared to be unaffected by either TGF-b or PDGF, as
judged from the band patterns obtained by RT-PCR. All
splice variants were still produced and no major differences
were visible. Though not a quantitative method, important
changes can be recognized by calculating the ratio between
the different PCR products of the same sample [33].
TGF-b also did not affect splicing at the IIICS region.
Fig. 7. Analysis of the IIICS splice variants in TEC. The IIICS region contains three potential splice sites (schematically shown in A) giving rise to five
different mRNA (shown as shaded bars). With use of primers flanking the IIICS region (PCS2 and PCS1) the five PCR products were obtained (B shows
the autoradiography of 2 independent RT-PCR reactions). The relative percentage of the different PCR was calculated. V95 and V89 were separated
using the two other primer pairs (PCS3/PCS1or PCS2/PCS4) (B right panel; ethidium bromide gels are shown). On lane M the DNA size markers were
separated (from top: 2176, 1756, 1230, 1033, 653, 517, 453, 394, 298, 234, 154 bp). With use of the flanking primers (PCS2/PCS1) the band pattern of
TEC, stimulated with PDGF (C), or TGF-b (D) for various times was analyzed (ethidium bromide agarose gels are shown).
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When analyzing IIICS after stimulation with PDGF at the
times of maximal stimulation (2 hr and 4 hr) the band
pattern and the semiquantitative analysis point to a slight
reduction of V120. Whether this reflects a different splicing
(such as, loss of CS1 or CS5) is not known, because the
ratio of V89 to 120 or of V95 to V120 could not be
determined with sufficient accuracy by the method em-
ployed.
Analyzing EDA splicing by the same method revealed
that following TGF-b stimulation the portion of EDA
cDNA increased from 30% of total FN to 45%, confirming
the earlier data obtained by Northern blotting that TGF-b
preferentially up-regulated the EDA-containing FN [17].
PDGF did not affect the splicing at the EDA site as tested
by Northern blotting and RT-PCR as well.
Like many other cells TEC synthesize PDGF and
TGF-b, which are released and accumulate in the super-
natant over time. In contrast to other cells, such as mesan-
gial cells [34, 35], the release of cytokines was not enhanced
by either TGF-b or PDGF in the current study. As sug-
gested for PDGF, additional signals appear to be required
for efficient TGF-b release [36]. These findings rule out the
possibility that effects seen after stimulation with PDGF or
with TGF-b might partly be due to secondarily induced
cytokines.
The conclusion that PDGF and TGF-b act indepen-
dently of each other is supported by the differences seen
between the TGF-b- and PDGF-mediated effects. TGF-b
but not PDGF affect the splicing at the EDA site, while in
PDGF-treated TEC the increase in abundance of FN
mRNA occurred earlier and was more transient than in
cells stimulated with TGF-b. TGF-b appeared also to be
the more potent stimulator, particularly with regard to the
induction of fibronectin protein synthesis.
The different effects of TGF-b and PDGF on fibronectin
synthesis correlate well with in vivo observations by others,
and though both PDGF and TGF-b are thought to partic-
ipate in the development of sclerosis, there are important
differences. A constant presence of TGF-b, for example,
induces fibronectin deposits and development of sclerosis,
whereas PDGF induces hypercellularity, most probably by
stimulating cell proliferation [27, 37]. Moreover, in exper-
imentally-induced nephropathies, expression of PDGF dif-
fers from TGF-b with regard to the kinetics and the
distribution in the tissue [38–41]. Moreover, the enhanced
formation of the EDA-containing FN-splice variant in
response to TGF-b has an in vivo correlate: in human
disease as well as in experimentally-induced nephropathy
TGF-b synthesis is associated with deposition of EDA-
containing fibronectin and the pathological accumulation
of extracellular matrix [13, 26]. Whether the expression of
EDA changes the properties of fibronectin in a way to favor
matrix accumulation is not yet known, however, it appears
to be an attractive hypothesis for further studies.
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APPENDIX
Abbreviations used in this article are: FN, fibronectin; PBS, phosphate
buffered saline; PDGF, platelet-derived growth factor; RT-PCR, reverse
transcribed-polymerase chain reaction; TEC, tubular epithelial cells;
TGF-b, transforming growth factor beta.
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